In breast cancer, a αFGF-binding peptide, AP8, isolated by phage display technology, provided an effective αFGF/FGFRs antagonist that might have potential applications in the treatment of breast cancer, characterized by the upregulation of αFGF/FGFRs23. This evidence concerns the gene FGF1 and breast carcinoma.